trending Market Intelligence /marketintelligence/en/news-insights/trending/q9jHVox-16te4yLaYpW1cA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioMarin offering senior subordinated convertible notes

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioMarin offering senior subordinated convertible notes

BioMarin Pharmaceutical Inc. plans to sell $450 million of senior subordinated convertible notes due 2024 in an underwritten offering.

The company also granted the underwriters an option to buy up to an additional $50 million of notes.

BioMarin plans to use a majority of the net proceeds from the offering to repay, repurchase or settle in cash some or all of its 0.75% senior subordinated convertible notes due in October 2018, although it does not intend to effect any such repayment or repurchase concurrently with the offering.

The remaining net proceeds will be used for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to the manufacturing capability for its gene therapy program.

The notes will be convertible into BioMarin's common shares plus, if applicable, cash in lieu of any fractional share.

BofA Merrill Lynch is acting as book-running manager for this offering. J.P. Morgan and Goldman Sachs & Co. are acting as joint book-runners.